Advisory board compensation benchmarks in biotech consulting

Yet only 13% of surveyed physicians currently serve or have served on a pharmaceutical advisory board, while 65% say they have never been invited. That gap is not a distribution problem. It is a structural one.

The fastest-expanding corner of medical consulting is still operating with compensation frameworks that often confuse the people they are designed to recruit. The result is a quiet, persistent failure of market function. Biotech medical advisory board compensation benchmarks do not simply determine what a medical director or physician advisor gets paid. They influence who accepts a seat at the table, which clinical judgments inform pipeline decisions, and how defensible the relationship remains under regulatory scrutiny.

The operational reality is straightforward: compensation is part of advisory board design, not an administrative detail to settle after the scientific strategy has been agreed.

The Market Behind the Advisory Seat

Physician advisory services have moved from a peripheral consulting arrangement to a core strategic input inside biotech and pharmaceutical companies. The global market reached $4.25 billion in 2023, according to Grand View Research, with projected growth at a 6.8% CAGR through 2030. That expansion reflects more than demand for additional consultants. It reflects a change in how sponsors use clinical expertise.

Three forces are pushing advisory work closer to the center of company decision-making:

• Pipeline complexity. Sponsors need specialist clinical judgment earlier, often before a program has generated the data that would traditionally attract established key opinion leaders.
• Fractional and interim medical leadership. Early-stage companies can access senior expertise without carrying the cost of a full-time executive structure.
• Investor and board scrutiny. Biotech companies are expected to demonstrate credible scientific governance before major capital commitments, pivotal studies, partnerships, or transactions.

An advisory board may now be involved in indication selection, endpoint strategy, trial feasibility, investigator mapping, regulatory preparation, data interpretation, and early commercial positioning. In some companies, the board is also a source of credibility during fundraising and business development. That broader role changes the compensation question. A sponsor is not paying only for attendance at a quarterly meeting; it may be paying for access to judgment that affects the value and direction of an asset.

The Sermo data sharpens the other side of the picture. Of the physicians surveyed, 13% currently serve or have served on a pharmaceutical advisory board. The remaining respondents include a 65% majority who have never been invited. For sponsors, this is not an interesting statistic to place in an investor deck. It is a bottleneck.

A compensation framework that under-scales the work, relies too heavily on uncertain equity, or cannot satisfy a fair market value review shrinks the eligible advisor pool precisely when demand for specialist input is increasing. The result is predictable: the same small group of visible experts receives repeated invitations, while qualified physicians outside established networks remain underused.

An advisory board is only as deep as the compensation framework that recruits to it. A confusing or indefensible pay structure can cost a sponsor access to the clinical judgment it needs most.

The advisory board is no longer a courtesy appointment at the back end of a Phase II program. It sits inside due diligence workflows, regulatory strategy, KOL mapping, and early asset positioning. Compensation design has to match that operating weight.

Equity-Driven Compensation in Early-Stage Biotech Startups

Pre-seed, seed, and Series A biotech sponsors rarely pay substantial cash retainers to scientific advisors. Equity is the dominant instrument, but the existence of an equity component does not make an offer self-explanatory or automatically attractive. The bandwidth of early-stage equity is wide, and physicians often lack the information needed to convert a percentage into a realistic view of value.

Startup advisory board grants typically fall between 0.1% and 1% of equity, vested over one to two years. The range is not a universal tariff. It reflects the stage of the company, the advisor’s reputation, the expected workload, the scarcity of the relevant expertise, and whether the individual is providing occasional counsel or functioning as an extension of the founding team.

Two structural patterns are common:

• Founding-stage advisors who provide hands-on support during IND-enabling work, help identify clinical sites, review therapeutic positioning, or participate in investor and partner discussions may command closer to the upper end of the range. Their grants may include shorter vesting periods or milestone-linked provisions tied to clearly defined deliverables.
• Later-stage advisors joining a more mature scientific advisory board and attending quarterly meetings generally receive a smaller grant, often around 0.1% to 0.25%, with standard time-based vesting and a narrower scope of work.

The headline percentage is only one part of the offer. The instrument can matter just as much:

• Options and restricted stock carry different tax and ownership consequences.
• The strike price of an option should be considered in relation to the company’s most recent 409A valuation.
• A vesting cliff can delay any realized ownership.
• The post-termination exercise window may determine whether an advisor can afford to retain the grant after leaving.
• Dilution from future financing rounds can materially change the eventual ownership percentage.
• Milestone-based vesting requires precise definitions of completion and acceptance.

A 0.5% option grant with a five-year post-departure exercise window is a meaningfully different instrument from a 0.5% restricted stock grant with a 90-day exercise window after termination. Treating both offers as equivalent because the percentage is identical is a basic compensation error.

Advisors frequently under-value these grants because they arrive without cash clarity. That is a structural problem on both sides of the negotiation. The physician cannot weigh the offer against other commitments, and the sponsor cannot explain the relationship clearly to its board, finance team, or compliance reviewers.

The practical solution is not to bury the equity terms in a long-form agreement. Give the advisor a one-page summary that states:

• the type of instrument;
• the number of shares or the percentage used to calculate the grant;
• the relevant capitalization basis;
• the strike price, where applicable;
• the vesting start date and cliff;
• the total vesting horizon;
• any milestone conditions;
• the consequences of termination; and
• the post-termination exercise window.

That summary does not replace legal documentation. It makes the economic logic legible before the physician commits time and reputation to the company.

Early-stage sponsors should also distinguish between a true advisory role and a disguised operating role. An advisor who is expected to lead clinical planning, manage vendors, participate in regulatory meetings, recruit staff, or make decisions on behalf of the company is not simply providing periodic scientific counsel. The equity may need to be assessed alongside a consulting or fractional executive arrangement, with a separate scope and separate compliance analysis.

Structuring Cash Retainers and Honoraria for Growth-Stage Ventures

Once a biotech reaches Series B or approaches pre-IPO maturity, compensation often shifts. The advisor’s time commitment rises, governance expectations tighten, and cash enters the picture alongside equity. Monthly cash retainers for growth-stage advisors typically run between €500 and €3,000, calibrated by advisor profile and depth of involvement.

The range is useful only when the sponsor can explain what moves an engagement from €500 toward €3,000. Four factors usually do the work:

1. Time commitment. A quarterly meeting with limited asynchronous review belongs at the lower end. Monthly committee work, repeated protocol review, endpoint discussions, or recurring access to the advisor’s expertise support a higher retainer.

2. Specialty scarcity. Therapeutic areas with thin specialist populations, including rare disease, gene therapy, and radiopharmaceuticals, can require a premium because the relevant expertise is difficult to replace.

3. Regulatory exposure. An advisor reviewing an IND submission, supporting regulatory meeting preparation, or participating in a data safety monitoring structure may carry greater personal and professional exposure than someone providing general strategic commentary.

4. Strategic depth. Participation in investor presentations, M&A due diligence, partnership discussions, or clinical development decisions moves the engagement beyond a routine advisory board seat.

The sponsor should not use the retainer as a substitute for defining the work. The contract should specify expected meetings, preparation, response times, document review, travel, confidentiality, publication issues, and the circumstances under which additional work requires a separate statement of work.

Per-meeting honoraria remain common, but there is no universal industry-wide cap that resolves the question for every sponsor or therapeutic area. A mature structure may combine a base retainer with a meeting fee that applies only when the meeting exceeds a defined duration or requires material preparation. That approach connects payment to actual work while making the arrangement easier to explain in an FMV review.

Do not pay advisors like consultants and contract them like employees. Decide whether the engagement is strategic retainer work, project-based consulting, or fractional medical leadership. Mixing the categories creates a structure that neither side can describe consistently.

A practical framework for growth-stage advisory cash might look like this:

These figures are starting points for structuring a discussion, not automatic entitlements. The appropriate amount still depends on the physician’s experience, the work required, the therapeutic area, the geography, the company’s FMV process, and whether the engagement includes deliverables outside the advisory board’s remit.

When an Advisory Seat Becomes a Consulting Role

Fractional medical director engagements deserve their own contract architecture. They are not advisory board seats. A fractional medical director may exercise decision-making authority, assume regulatory signatory responsibilities, manage clinical vendors, supervise employees, or carry operational accountability. Those responsibilities pull the relationship outside a conventional advisory compensation model.

The distinction matters for several reasons:

• The expected time commitment is more predictable and more substantial.
• The company may rely on the individual’s decisions rather than simply receiving independent advice.
• Deliverables and performance expectations are easier to document.
• Professional liability and indemnification questions become more prominent.
• The compensation may need to reflect executive or consulting market conditions rather than meeting-based honoraria.

A sponsor that labels an operational role an advisory board appointment may create confusion in payroll, tax, governance, and compliance records. A physician who accepts an operating workload under an advisory label may also discover that the compensation does not reflect the actual exposure.

Public Biopharma Board Governance: Balancing Cash and Equity Incentives

Public biotech and pharmaceutical companies operate under a different compensation logic. SEC disclosure requirements, stockholder scrutiny, related-party policies, equity plan rules, and a more elaborate governance structure all affect how board and advisory payments are set.

The headline benchmark in the draft market data is that board chair base retainers at public biopharma companies sit at a $70,000–$75,000 median across market-cap tiers. Equity represents around 60% of total board fees, compared with roughly 40% in cash. Those figures describe public-company board compensation, not a default rate for scientific advisors.

The distinction is essential. A statutory director has fiduciary responsibilities and governance duties that differ from those of a physician serving on a scientific advisory board. Benchmarking a non-director advisor against a public-company board chair can overstate the appropriate payment and weaken the sponsor’s FMV rationale. The reverse is equally problematic: treating a director’s responsibilities as if they were equivalent to quarterly scientific consultation understates the role.

Equity-heavy compensation at the public board level functions as a long-term alignment mechanism. It connects part of the director’s economic interest to the company’s continuing performance rather than paying entirely for attendance or short-term activity. Scientific advisory board members who are not statutory directors may receive equity, but the rationale, vesting, disclosure treatment, and approval process can be different.

Key structural features to address in public-biopharma advisory contracts include:

• Annual retainers calibrated to the expected advisory or committee load.
• Meeting fees separated from the retainer, with caps or assumptions tied to the expected number of meetings.
• Equity grants documented through the company’s applicable equity plan and approved through the appropriate governance process.
• Per-meeting honoraria for scientific advisory board members set at levels consistent with the company’s most recent FMV analysis.
• Expense treatment covering travel, accommodation, preparation, and other reasonable costs without turning reimbursement into an unstructured benefit.
• Conflict and independence disclosures addressing other board positions, consulting arrangements, royalty interests, and relationships with company counterparties.

An advisory board seat at a public biopharma company may also intersect with the issuer’s related-party transaction policy. A physician who sits on multiple boards, holds a separate consulting contract with the company, receives royalties, or has a financial relationship with a trial site may trigger disclosure questions or independence concerns.

Conflict screens should be built into the engagement letter, not conducted after the relationship has started. The company should know whether the advisor has obligations to competitors, institutional affiliations that limit participation, investigator relationships that affect trial decisions, or other financial interests connected to the program.

Navigating Compliance and Fair Market Value in Advisor Contracts

Medical consultant fee transparency is no longer a matter of presentation style. It is part of the control environment around the engagement. Sponsors need a compensation structure that is understandable to the advisor, consistent with the work, and defensible if reviewed by a compliance function, board committee, auditor, regulator, or business partner.

Fair market value is not established simply because two parties agree on a number. The sponsor should be able to explain why the payment is appropriate for the services requested and how the amount was determined. A physician advisory board contract that cannot survive an FMV challenge is a liability waiting to mature.

Three operational priorities keep the framework defensible.

Document the FMV rationale

Anchor every engagement to a documented FMV assessment. Independent valuation specialists and third-party compensation surveys specific to physician advisory work can provide useful reference points. Internal compensation bands may also help, provided they are based on a consistent methodology and updated when the nature of the work changes.

The file should explain the factors considered, which may include:

• the advisor’s specialty and level of experience;
• the scarcity of the relevant clinical expertise;
• the expected time commitment;
• the complexity of the materials to be reviewed;
• the number and duration of meetings;
• the scope of any written deliverables;
• the advisor’s regulatory or operational responsibilities;
• travel and preparation requirements; and
• whether equity forms part of the total package.

A recruiter’s estimate or an informal range passed through a professional network is not a substitute for a documented FMV process. Nor is a historical payment that has simply been rolled forward without checking whether the scope has changed.

Separate distinct instruments and services

Separate the advisory engagement from the equity grant and from any project-based consulting work. A single agreement that mixes advisory duties, consulting deliverables, executive responsibilities, and equity vesting triggers can create uncertainty around tax treatment, scope, and FMV defense.

Each relationship should have its own logic:

• The advisory agreement should define independent scientific or clinical counsel.
• A consulting statement of work should identify specific deliverables, timelines, and acceptance criteria.
• A fractional medical leadership agreement should address authority, accountability, availability, and operational responsibilities.
• The equity documentation should identify the instrument, vesting terms, exercise mechanics, and treatment on termination.

This is not unnecessary paperwork. It prevents a sponsor from paying a general honorarium for work that is actually a consulting project, and it prevents an advisor from assuming that equity compensates for responsibilities that were never clearly described.

Put departure terms in writing

Termination, replacement, and post-engagement exercise language belong in the agreement from the beginning. The advisor should understand what happens to unvested equity, vested options, meeting fees, unpaid invoices, confidentiality duties, and work product when the relationship ends.

The post-departure exercise window can materially affect the value of an option grant. So can provisions dealing with a change of control, a company-initiated termination, a resignation for good reason, or a conflict that prevents continued participation. These provisions should not be left to a later side letter or an informal explanation from a founder.

A clean exercise window can allow a departing advisor to remain a long-term shareholder. A grant that collapses on departure may provide little realized value even if the headline percentage looked compelling. Either outcome can be defensible if it is stated clearly and applied consistently. The problem is not that every advisor must receive identical terms. The problem is when the terms are unclear until after the advisor has committed time.

Keep compliance standards connected to the real work

Compliance standards for advisor honoraria are strongest when the agreement reflects what actually happens in practice. If the physician is expected to prepare extensively, review confidential datasets, attend recurring committee meetings, or help shape regulatory strategy, those responsibilities should appear in the scope and in the compensation rationale.

The company should also control basic process issues:

• payments should be made through the approved vendor and accounts-payable process;
• services should be documented before payment;
• expenses should follow the company’s reimbursement policy;
• conflicts should be reviewed before engagement and when circumstances change;
• compensation should be reassessed if the scope expands;
• records should be retained according to the company’s compliance and governance requirements.

The specialists who command premium rates are not necessarily the people with the most aggressive demands. They are often the people whose roles are clearly scoped, properly documented, and supported by a defensible FMV opinion. That documentation becomes a competitive advantage as boards professionalize and sponsors face more scrutiny over how clinical influence is obtained.

The Mandate

A biotech organization’s advisory board compensation framework is operating infrastructure, not a courtesy. Treat it accordingly.

For sponsors, that means publishing internal compensation bands, reviewing FMV for each advisory seat at appropriate intervals, and giving every physician a clear summary of the economic terms before the engagement begins. It means distinguishing a scientific advisory role from a consulting project and a fractional medical leadership position. It also means accepting that a lower headline payment is not necessarily cheaper if it produces unclear expectations, repeated renegotiation, or the loss of a critical advisor.

For physician advisors, it means refusing to evaluate equity on percentage alone. The instrument, strike price, vesting schedule, dilution assumptions, termination provisions, and post-departure exercise window all affect the value of the offer. A cash retainer should be considered alongside the time commitment, preparation burden, regulatory exposure, and whether the company is asking for strategic advice or operational responsibility.

For both sides, transparency is not a concession. It is the mechanism that makes the relationship workable.

The 87% of surveyed physicians who do not currently serve or have not served on a pharmaceutical advisory board should not be treated as structurally inaccessible. Some have never been approached. Others may have declined arrangements that were poorly defined, undercompensated, or administratively difficult to defend. Better compensation design will not solve every recruitment problem, but it removes one of the most avoidable barriers.

The advisory board is a load-bearing part of biotech governance. Build its compensation model with the same discipline applied to the clinical strategy, the regulatory plan, and the capitalization table.